Brief: Ascentage Pharma Group International Says HY Loss Attributable RMB406.7 Mln
26/08/2022 16:37
Aug 26 (Reuters) - Ascentage Pharma Group International
6855.HK :
* HY LOSS ATTRIBUTABLE RMB406.7 MILLION VERSUS LOSS RMB376.7
MILLION
* HY REVENUE RMB95.8 MILLION VERSUS RMB13 MILLION
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up